Regeneron Pharmaceuticals Dividend
Dividend criteria checks 0/6
Regeneron Pharmaceuticals does not have a record of paying a dividend.
Key information
n/a
Dividend yield
n/a
Payout ratio
| Industry average yield | 2.7% |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | US$0 |
| Earnings per share | US$39.05 |
| Dividend yield forecast in 3Y | 0% |
Recent dividend updates
No updates
Recent updates
Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Apr 17
Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Intrinsic Value Is Potentially 46% Above Its Share Price
Feb 03We Think Regeneron Pharmaceuticals (NASDAQ:REGN) Can Stay On Top Of Its Debt
Jan 16Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 39% Undervaluation?
Oct 28Regeneron, Bayer Eylea gets FDA priority review for eye disorder in infants
Oct 12Regeneron Pharmaceuticals (NASDAQ:REGN) Could Easily Take On More Debt
Oct 10Sanofi, Regeneron win FDA label expansion for Dupixent in chronic, skin condition
Sep 29Regeneron: Fortune Seems To Favor This Bold, Innovative Pharma
Sep 14Regeneron says pivotal trials for less frequent Eylea injections reached main goals
Sep 08Regeneron: There Are Challenges But Growth To Resume In 2023
Aug 25Regeneron monoclonal antibody gets WHO recommendation for Ebola
Aug 19Regeneron IPR hearing suggests Eylea patent may be in trouble - analyst
Aug 11Regeneron Pharmaceuticals Non-GAAP EPS of $9.77 beats by $1.02, revenue of $2.86B beats by $60M
Aug 03Is Now The Time To Put Regeneron Pharmaceuticals (NASDAQ:REGN) On Your Watchlist?
Jul 26Regeneron Post COVID Bolus
Jul 16Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Jul 08FDA accepts Regeneron's application for Eylea extended regimen to treat diabetic blindness
Jun 29Regeneron Pharmaceuticals: Lack Of Appreciation For The Purchase Of Libtayo
Jun 21Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Could Be 47% Below Their Intrinsic Value Estimate
Jun 05Regeneron's Growth Set To Slow, But Could Outperform Downbeat Consensus Forecasts
May 21Dividend Yield vs Market
| Regeneron Pharmaceuticals Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (REGN) | n/a |
| Market Bottom 25% (US) | 1.7% |
| Market Top 25% (US) | 5.1% |
| Industry Average (Biotechs) | 2.7% |
| Analyst forecast in 3 Years (REGN) | 0% |
Notable Dividend: Unable to evaluate REGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate REGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
| Month | Dividend Per Share (annual) | Avg. Yield (%) |
|---|---|---|
| 12/31/2025 | - | 0% |
| 12/31/2024 | - | 0% |
| 12/31/2023 | - | 0% |
Stable Dividend: Insufficient data to determine if REGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if REGN's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as REGN has not reported any payouts.